Background: Chronic kidney disease (CKD) is a well-established risk factor for adverse events in patients undergoing percutaneous coronary intervention (PCI). However, few data exists on the subsequent healthcare resource use and related incremental costs in this patient subgroup. The present study compares the rates of cardiac-related hospitalisations and the associated direct costs, post-PCI in patients with and without CKD.
Methods: Healthcare costs were estimated for 12,998 PCI patient-procedures from the Melbourne Interventional Group (MIG) registry, collected between February 2004 and October 2010. Information collected included the use of cardiovascular drugs and cardiac-related hospitalisations from those that completed 12-month follow-up. Individual patients were assigned unit costs based on published data from the National Hospital Cost Data Collection for Admissions in Victoria (2008-2009) and the Pharmaceutical Benefit Scheme (PBS) schedule (2011-2012). Bootstrap multiple linear regression was used to estimate the direct excess healthcare costs, adjusting for age and gender and relevant comorbidities.
Results: Excess cardiac-related readmissions occurred among patients with "severe CKD or dialysis" (estimated glomerular filtration rate (eGFR): <30 ml/min/1.73 m(2); n = 330; 35%), compared to "moderate CKD" (eGFR: 30-60 ml/min/1.73 m(2); n = 2648; 28%), or the "referent CKD status" (eGFR: ≥ 60 ml/min/1.73 m(2); n = 10,020; 24%). On average, excess (95%CI) overall direct costs were significantly higher in patients with severe CKD or dialysis compared to those with referent CKD status [$AUD 2206 ($AUD 1148 to 3688)].
Conclusions: From the healthcare payer's perspective, PCI patients with severe CKD compared to no-CKD imposed significantly higher burden on subsequent healthcare resources. Hospitalisations accounted for the majority of these expenditures.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2013.03.128 | DOI Listing |
EuroIntervention
January 2025
Hospital Clínico San Carlos IDISSC, Complutense University of Madrid, Madrid, Spain and Centro de Investigación Biomédica en Red - Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Background: Safe deferral of revascularisation is a key aspect of physiology-guided percutaneous coronary intervention (PCI). While recent evidence gathered in the FAVOR III Europe trial showed that quantitative flow ratio (QFR) guidance did not meet non-inferiority to fractional flow reserve (FFR) guidance, it remains unknown if QFR might have a specific value in revascularisation deferral.
Aims: We aimed to evaluate the safety of coronary revascularisation deferral based on QFR as compared with FFR.
Eur Heart J
January 2025
Center of Excellence of Cardiovascular Sciences, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy.
Circ Cardiovasc Qual Outcomes
January 2025
Division of Cardiology, Department of Medicine, University of Washington, Seattle (J.A.D., E.J.S., D.H.A.).
Background: Case-based peer review of percutaneous coronary intervention (PCI) is used by many hospitals for quality improvement and to make decisions regarding physician competency. However, there are no studies testing the reliability or validity of peer review for PCI performance evaluation.
Methods: We recruited interventional cardiologists from 12 Veterans Affairs Health System facilities throughout the United States to provide PCI cases for review.
Front Cardiovasc Med
December 2024
Department of Cardiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Background: Acute myocardial infarction (AMI), particularly ST-segment elevation myocardial infarction (STEMI), significantly impacts global health, exacerbated by risk factors such as diabetes mellitus (DM). While the Gensini score effectively quantifies coronary artery lesions, its correlation with fasting blood glucose (FBG) levels, particularly in a non-linear fashion, has not been thoroughly explored in STEMI patients.
Methods: This study analyzed data from 464 STEMI patients treated with percutaneous coronary intervention at the First People's Hospital of Taizhou City, Zhejiang Province, China, from January 2010 to October 2014.
Cureus
December 2024
Medical Strategic Affairs, Torrent Pharmaceuticals Ltd., Ahmedabad, IND.
Introduction: Elevated central aortic pressure, cardiac output and peripheral vascular resistance contribute to high morbidity in relation to end organ dysfunction in obstructive and non-obstructive coronary artery disease (NOCAD) cases despite revascularization. Bisoprolol preempts further progression of left ventricular dysfunction in such cases due to anti-ischemic and anti-hypertensive effects, further extending its evaluation in local Indian settings.
Methods: Post-hoc analyses of NOCAD patients with epicardial stenosis (N=378, 30 to 70% stenosis) from cross-sectional analyses conducted across eighty centers in India.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!